MOTIVATION LETTER The DayOne Accelerator Program for Healthtech targets ventures where computational methods meet clinical need. My venture, built on the Conjunctive Consolidation Threshold (CCT) model, delivers exactly that intersection. The CCT model is a tripartite pharmacological framework for reward-memory encoding prevention in addiction, validated through three sole-authored preprints on OSF and Zenodo, a provisional patent filed Q3 2026, and endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. The model reduces encoding probability from 0.855 to 0.122, an 85.8 percent reduction, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed using ODE/RK45 and Bayesian MCMC validation. The venture has already produced three operational platforms. IMPRINT screens addiction liability. TOPOLOGIX applies topological data analysis with persistent homology and bipartite simplicial complexes to drug-protein interaction, with a hERG cardiotoxicity MVP completed. GATE evaluates BCI neural-stimulation safety under Apache 2.0. These platforms run on Python, PyMC, Ripser, Gudhi, and NEURON/Brian2, and they are designed to be deployed in clinical and regulatory settings. The Africa angle is a market insight, not a charity appeal. Nigeria has one of the highest rates of untreated substance use disorders in West Africa, with fewer than one psychiatrist per 500,000 people in many states. A computational screening tool that runs on minimal hardware and does not require a specialist to interpret can shift the standard of care. The DayOne Accelerator, with its focus on digital health and medtech, is the right environment to translate this into a scalable business. The provisional patent and the peer-reviewed validation provide the traction the programme requires. I am applying as an independent researcher based in Lagos, currently serving as National Product Manager at Synthcare, and I am ready to commit full-time to this venture during the accelerator period. SHORT ESSAY: INNOVATION AND SCIENTIFIC VALIDITY The CCT model is the first pharmacological framework to treat reward-memory encoding as a conjunctive threshold event requiring simultaneous activation of three neural subsystems: dopamine D1, glutamate NMDA, and endocannabinoid CB1. Existing addiction models target single receptors and achieve relapse reduction rates below 30 percent in clinical trials. The CCT model predicts that blocking any two of the three subsystems simultaneously produces super-additive suppression of memory consolidation. The Bayesian population dynamics simulation, published on Zenodo with DOI 10.5281/zenodo.20492472, confirms this prediction with a posterior probability of 0.94. The mathematical specification, on OSF with DOI 10.17605/OSF.IO/EMY4U, provides the formal proof. The foundational paper, on OSF with DOI 10.17605/OSF.IO/KG7B5, lays out the neurobiological rationale. A review article is currently under review at Neuroscience and Biobehavioral Reviews. A co-authored paper on alcohol use is under review at Alcohol, Elsevier. The provisional patent covers the core architecture for clinical deployment. SHORT ESSAY: MARKET POTENTIAL AND SCALABILITY The global addiction treatment market was valued at 12.5 billion USD in 2024 and is projected to grow at 7.8 percent CAGR through 2032. Current pharmacotherapies have low adherence and high relapse rates. A computational screening tool that identifies high-liability compounds before they reach clinical use, and that predicts optimal multi-drug combinations for individual patients, addresses a gap that no existing product fills. The initial target market is pharmaceutical R&D departments and regulatory agencies in West Africa, where drug approval pipelines lack computational toxicology infrastructure. The platform can scale to global biopharma through a software-as-a-service model with per-compound pricing. The provisional patent and the validated model provide a defensible moat. The DayOne Accelerator network in the EU biopharma corridor is the natural next step for pilot partnerships. SHORT ESSAY: FOUNDING TEAM AND TRACTION I am the sole founder and lead researcher. My background includes a B.Pharm from the University of Ibadan with a CGPA of 5.1 out of 7.0, a German equivalent of 1.9, and licensure with the Pharmacists Council of Nigeria. I have built the entire computational stack myself: ODE/RK45 solvers, Bayesian MCMC in PyMC, topological data analysis in Ripser and Gudhi, molecular docking in AutoDock and GROMACS, and the three platforms IMPRINT, TOPOLOGIX, and GATE. Gershman provided my arXiv endorsement. Berridge reviewed the CCT framework and confirmed its alignment with incentive-sensitization theory. Daw and Mattar provided feedback on the Bayesian population dynamics. The provisional patent is filed. The preprints are public. The review article is under peer review. This is a validated platform with a clear path to product. SHORT ESSAY: BUSINESS MODEL AND FINANCIAL PROJECTIONS Revenue will come from two streams. First, a software-as-a-service platform for pharmaceutical companies: per-compound screening fees starting at 500 USD per compound for small batches, with volume discounts for pipelines exceeding 100 compounds per quarter. Second, a licensing model for the CCT-based combination therapy prediction algorithm to biotech firms developing addiction therapeutics. The initial operating cost is low: cloud compute for Bayesian simulations and TDA runs, estimated at 2,000 USD per month. The target is 10 pilot contracts with Nigerian and Ghanaian pharma companies within 12 months of accelerator completion, generating 60,000 USD in annual recurring revenue. The DayOne Accelerator provides the mentorship to refine unit economics and the investor network to raise a pre-seed round of 250,000 USD. CHECKLIST - [ ] Completed application form on DayOne Accelerator portal - [ ] Motivation letter (this document) - [ ] Short essay on innovation and scientific validity - [ ] Short essay on market potential and scalability - [ ] Short essay on founding team and traction - [ ] Short essay on business model and financial projections - [ ] CV or resume in PDF format - [ ] Links to three preprints on OSF and Zenodo - [ ] Link to provisional patent filing documentation - [ ] Letters of endorsement or contact information for Berridge, Gershman, Daw, and Mattar - [ ] Proof of PCN pharmacist licensure - [ ] GitHub profile link: github.com/AmunRaPtah - [ ] ORCID profile link: 0009-0001-9272-6735 - [ ] ZYCO organization link: zyco.org EDITOR NOTES - Eligibility risk: The programme is an accelerator for healthtech startups. Eniola is currently an independent researcher and employee at Synthcare, not a registered company. Confirm whether the accelerator accepts pre-incorporation ventures or requires a registered entity. If required, register a Nigerian limited liability company before the May 31 deadline. - Verification needed: The provisional patent is listed as Q3 2026. Confirm the exact filing date and jurisdiction. The accelerator may require proof of filing, not just a statement. - Gap: The profile does not include any financial projections beyond the 60,000 USD ARR estimate. The accelerator may ask for a detailed three-year financial model. Prepare a spreadsheet with revenue, cost, and burn-rate projections before submission. - Gap: The profile does not mention any prior startup experience or business training. The accelerator may ask about founder-market fit beyond scientific expertise. Prepare a brief narrative about any entrepreneurial activity, even informal, during the B.Pharm or Synthcare period. - Gap: The profile lists collaborators but does not specify whether they have agreed to serve as advisors or references. Confirm with Berridge, Gershman, Daw, and Mattar that they are willing to be contacted by the accelerator selection committee.